Introduction
============

Breast cancer has been the most common type of cancer and the main cause of cancer death among women in the world, which was estimated to have 1.7 million new cases in 2012 ([@ref-24]). Breast cancer is an extremely heterogeneous disease in the clinic and the potential molecular mechanism of carcinogenesis has not been clearly understood so far. In recent years, inherited factors were identified to play a critical role in the development of breast cancer ([@ref-20]).

Researches on the field of tumour immunology found that the immune system can influence tumour occurence during the period of elimination, equilibrium and escape ([@ref-4]). Cytotoxic T-lymphocyte antigen-4 (CTLA-4), which was also designated as CD152, expressed mainly on activated T cells. As an immunosuppressive cytokine, it can inhibit T-lymphocyte proliferation and activation ([@ref-22]). Numerous researches have demonstrated that blockage of CTLA-4 function can improve antitumor immunity ([@ref-15]; [@ref-21]; [@ref-25]). This indicates CTLA-4 may exert positive effects on carcinogenesis. The human *CTLA-4* gene, which is located in human chromosome 2q33, is one of the most important genes involved in immune responses to a variety of antigens ([@ref-26]). *CTLA-4* gene comprises four exons and has several important polymorphisms in the entire region, including the +49G\>A ([rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775)) in exon 1 ([@ref-3]), the +6230G\>A ([rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243)) in 3^′^-untranslated region ([@ref-11]), the −1661A\>G ([rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808)) and −1722 T\>C ([rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618)) in the promoter region ([@ref-12]), which are the most commonly studied single nucleotide polymorphisms (SNPs). These SNPs are important because they can alter the host immune response by affecting the transcription of *CTLA-4* gene, the expression of CTLA-4 protein, and the interaction of CTLA-4 and CD80 ligand ([@ref-1]; [@ref-22]; [@ref-29]).

Numerous investigations have demonstrated that *CTLA-4* genetic polymorphisms may have association with human breast cancer susceptibility ([@ref-6]; [@ref-9]; [@ref-16]; [@ref-17]; [@ref-18]; [@ref-22]; [@ref-28]; [@ref-34]; [@ref-13]). The results showed that some of the polymorphisms such as [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) and [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) may increase the breast cancer risk while other polymorphisms such as [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) and [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) may reduce the risk of breast cancer. Considering that a single study does not have enough power to detect the overall effects, we conducted a meta-analysis which is a statistical analysis of the data from some collection of studies in order to synthesize the results to obtain a more reliable evaluation of the relationship between the four common SNPs in *CTLA-4* gene and breast cancer susceptibility.

Materials and Methods
=====================

Our meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@ref-19]).

Search strategy
---------------

We searched the databases of EMBASE, PubMed, Web of Science, Wanfang, as well as Chinese National Knowledge Infrastructure (CNKI) to identify all the relevant articles up to July 18th, 2016. Keywords for search were: "CTLA-4 or Cytotoxic T-lymphocyte antigen 4 or CD152," "polymorphism or variation or SNP or [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) or [rs308724](http://www.ncbi.nlm.nih.gov/snp/?term=rs308724) or [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) or [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618)," and "breast cancer." The eligible article must be published in English or Chinese. References in retrieved articles were also searched manually.

Criteria for selection
----------------------

All studies selected for further meta-analysis must conform to the included criteria: (1) case-control study conducted in human and investigated the association of SNPs in *CTLA-4* with breast cancer susceptibility; (2) All the breast cancer patients were diagnosed by pathology or histology; (3) detailed data of the allele and genotype distributions are available; (4) the controls were cancer-free individuals. In addition, articles meet the following criteria were excluded: (1) articles that were reviews, conference abstracts, or repeat publications; (2) study design were based on family; (3) studies with no control groups. The quality of each included study was assessed by the Newcastle-Ottawa Scale for case-control studies ([@ref-30]).

Data extraction
---------------

According to the selection criteria, two authors (Zhiming Dai and Tian Tian) reviewed the literature independently and extracted the raw data and information from each eligible study including: first author, publication year, country of origin, racial ancestry, source of control, genotype method, total number of case and control, allele frequency and genotype distribution in case and control, and *P* value of HWE in control. Any discrepancy was discussed between authors and refereed by Zhijun Dai to reach a consensus.

Statistical analysis
--------------------

For each study, ORs and 95% CIs were computed to estimate the breast cancer risk associated with *CTLA-4* polymorphisms. Pooled ORs were calculated under the following genetic models: allele comparison of B *vs.* A, homozygote of BB *vs.* AA, heterozygote of AB *vs.* AA, dominant model of (BB + AB) *vs.* AA and recessive model of BB *vs.* (AA + AB). Heterogeneity among studies were estimated by *I*^2^ test and chi^2^-based Q statistic and significance was considered at *I*^2^\>50% ([@ref-10]). We adopted the random-effects model to analyze the combined ORs if *I*^2^ value was greater than 50%. Otherwise, a fixed-effects model should be exerted ([@ref-19]). We carried out subgroup analysis to estimate the specific effects of ethnicity and source of control. We also conducted a sensitivity analysis to assess the consistency and stability of our meta-analysis by omitting individual study in turn. Additionally, Begg's funnel plot and Egger's test were used to assess publication bias, and significance was identified as *P* \< 0.05 ([@ref-2]; [@ref-5]). All the statistical analyses were implemented with the Review Manager (Version 5.3; Cochrane Collaboration, London, UK) and STATA software (Version 12.0; Stata Corp, College Station, TX, USA).

Results
=======

Characteristics of included studies
-----------------------------------

Finally, nine articles comprising 10 studies investigating *CTLA-4* +49A\>G ([rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775)) and/or +6230G\>A ([rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243)) and/or −1722 T\>C ([rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618)) and/or −1661A/G ([rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808)) polymorphisms were identified for further analysis ([Fig. 1](#fig-1){ref-type="fig"}). [Table 1](#table-1){ref-type="table"} presented the characteristics of selected studies. Of the 10 studies, seven were from China, two were from Iran, and one was from India. Additionally, seven studies were based on population and three based on hospitals. Moreover, genotype distributions in the control group of each included studies complied with Hardy-Weinberg equilibriums (HWE) (*P* \> 0.05) except for one study for one SNP ([@ref-6]). The detailed data of the allele frequency and genotype distribution as well as HWE from each study were shown in [Table 2](#table-2){ref-type="table"}.

![Flow chart of the studies selection.](peerj-05-2815-g001){#fig-1}
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###### Characteristics of the studies included in the meta-analysis.

![](peerj-05-2815-g005)

  First author   Year    Country   Ethnicity   Genotyping medthod   Source of control   Total sample size (case/control)   SNP
  -------------- ------- --------- ----------- -------------------- ------------------- ---------------------------------- ---------
  Yu             2015    China     Chinese     PCR-RFLP             PB                  376/366                            1;2;3;4
  Minhas         2014    India     Indian      PCR-RFLP             PB                  250/250                            1
  Li D           2012    China     Chinese     PCR-RFLP             PB                  581/566                            1;2;3;4
  Kong           2010    China     Chinese     PCR-RFLP             HB                  315/322                            4
  Sun            2008a   China     Chinese     PCR-RFLP             PB                  1060/1070                          1
  Sun            2008b   China     Chinese     PCR-RFLP             PB                  1037/1070                          1
  Li H           2008    China     Chinese     PCR-RFLP             HB                  328/327                            2;3
  Wang           2007    China     Chinese     PCR-RFLP             PB                  117/148                            1;2;4
  Erfani         2006    Iran      Iranian     PCR-CTPP             PB                  283/245                            3;4
  Ghaderi        2004    Iran      Iranian     PCR-RFLP             HB                  197/151                            1

**Notes.**

PCRpolymerase chain reactionRFLPrestriction fragment length polymorphismCTPPconfronting two pairs primersPBpopulation basedHBhospital basedSNPsingle-nucleotide polymorphism

SNP No.1, +49A\>G ([rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775)); 2, +6230G\>A ([rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243)); 3, −1722T\>C ([rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618)); 4, −1661A\>G ([rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808)).
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###### Genotype distributions and allele frequencies of *CTLA-4* polymorphisms in cases and controls.

![](peerj-05-2815-g006)

  Study                                                                      Genotype (N)   Allele frequency (N)   *P* of HWE                                                               
  -------------------------------------------------------------------------- -------------- ---------------------- ------------ ----- ------- ----- ----- ----- ----- ------- ----- ------- -------
  +49A\>G ([rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775))                                                                                                                      
  [@ref-35]                                                                  376            174                    175          27    366     174   157   35    523   229     505   227     0.96
  [@ref-18]                                                                  250            111                    113          26    250     105   121   24    335   165     331   169     0.20
  [@ref-16]                                                                  576            49                     281          246   553     54    243   256   379   773     351   755     0.74
  [@ref-23]                                                                  1,060          101                    485          474   1,070   65    446   559   660   1,406   576   1,564   0.15
  [@ref-23]                                                                  1,037          100                    455          482   1,070   73    451   546   655   1,419   597   1,543   0.12
  [@ref-28]                                                                  117            48                     59           10    148     55    70    23    155   79      180   116     0.93
  [@ref-9]                                                                   197            84                     104          9     151     60    72    19    272   122     192   110     0.72
  +6230G\>A ([rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243))                                                                                                                  
  [@ref-35]                                                                  376            257                    110          9     366     252   103   11    624   128     607   125     0.90
  [@ref-16]                                                                  581            361                    197          23    566     361   182   23    919   243     904   228     0.99
  [@ref-17]                                                                  328            32                     124          172   327     20    114   193   188   468     154   500     0.57
  [@ref-29]                                                                  117            24                     47           46    148     18    56    74    95    139     92    204     0.16
  −1722T\>C ([rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618))                                                                                                                    
  [@ref-35]                                                                  376            123                    186          67    366     137   166   63    432   320     440   292     0.30
  [@ref-16]                                                                  574            184                    276          114   551     207   256   88    644   504     670   432     0.55
  [@ref-17]                                                                  328            125                    163          40    327     111   168   48    413   243     390   264     0.22
  [@ref-6]                                                                   282            225                    54           3     245     204   41    0     504   60      449   41      0.15
  −1661A\>G ([rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808))                                                                                                                  
  [@ref-35]                                                                  376            273                    91           12    366     281   78    7     637   115     640   92      0.56
  [@ref-16]                                                                  574            405                    153          16    551     425   115   11    963   185     965   137     0.33
  [@ref-13]                                                                  315            204                    105          6     322     241   76    5     513   117     558   86      0.72
  [@ref-28]                                                                  109            62                     45           2     148     111   35    2     169   49      257   39      0.68
  [@ref-6]                                                                   282            211                    65           6     238     184   43    11    487   77      411   65      0.001

**Notes.**

Athe major alleleBthe minor alleleHWEHardy-Weinberg equilibrium

Meta-analysis results
---------------------

Seven studies containing 3,613 cases and 3,608 controls focused on breast cancer risk with *CTLA-4* [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) polymorphism. As presented in [Table 3](#table-3){ref-type="table"}, significantly decreased risk was observed in the overall population in all the models except heterozygote (G *vs.* A: *OR* = 0.86, 95% CI \[0.80--0.92\], *P* = 0.000, [Fig. 2A](#fig-2){ref-type="fig"}; GG *vs.* AA: *OR* = 0.68, 95% CI \[0.57--0.81\], *P* = 0.000; GG *vs.* AA + AG: *OR* = 0.79, 95% CI \[0.71--0.87\], *P* = 0.000; AG + GG *vs.* AA: *OR* = 0.85, 95% CI \[0.74--0.97\], *P* = 0.02;). In subgroup analyses, [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) was also found to significantly reduce the breast cancer risk in Chinese and subgroup based on population under allelic, homozygous and recessive models.
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###### Meta-analysis results of *CTLA-4* polymorphisms and BC risk.
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  SNP                                                                        B *vs.* A           BB *vs.* AA   AB *vs.* AA         BB *vs.* AA + AB   AB + BB *vs.* AA                                                                    
  -------------------------------------------------------------------------- ------------------- ------------- ------------------- ------------------ ------------------- ----------- ------------------- ----------- ------------------- -----------
  +49A\>G ([rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775))                                                                                                                                                                    
  Overall                                                                    0.86 (0.80--0.92)   **0.000**     0.68 (0.57--0.81)   **0.000**          0.92 (0.80--1.06)   0.23        0.79 (0.71--0.87)   **0.000**   0.85 (0.74--0.97)   **0.02**
  Chinese                                                                    0.85 (0.79--0.92)   **0.000**     0.68 (0.56--0.82)   **0.000**          0.92 (0.73--1.16)   0.49        0.79 (0.71--0.88)   **0.000**   0.84 (0.65--1.08)   0.17
  PB                                                                         0.86 (0.80--0.93)   **0.000**     0.70 (0.59--0.84)   **0.000**          0.91 (0.78--1.05)   0.19        0.80 (0.72--0.89)   **0.000**   0.85 (0.69--1.04)   0.12
  +6230G\>A ([rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243))                                                                                                                                                                
  Chinese                                                                    0.87 (0.71--1.07)   0.20          0.68 (0.49--0.95)   **0.02**           0.99 (0.83--1.19)   0.94        0.77 (0.61--0.97)   **0.02**    0.87 (0.65--1.17)   0.36
  PB                                                                         0.91 (0.71--1.17)   0.48          0.75 (0.50--1.12)   0.15               1.03 (0.85--1.25)   0.76        0.77 (0.54--1.09)   0.14        1.00 (0.82--1.20)   0.99
  −1722T\>C (rs733618)                                                                                                                                                                                                                    
  Overall                                                                    1.09 (0.93--1.29)   0.29          1.15 (0.79--1.68)   0.47               1.13 (0.96--1.32)   0.15        1.11 (0.90--1.37)   0.32        1.14 (0.98--1.33)   0.09
  Chinese                                                                    1.07 (0.88--1.29)   0.51          1.12 (0.77--1.63)   0.55               1.12 (0.94--1.33)   0.22        1.10 (0.89--1.35)   0.39        1.11 (0.86--1.43)   0.43
  PB                                                                         1.19 (1.05--1.34)   **0.007**     1.37 (1.05--1.78)   **0.02**           1.22 (1.02--1.47)   **0.03**    1.21 (0.96--1.54)   0.11        1.26 (1.06--1.50)   **0.01**
  −1661A\>G ([rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808))                                                                                                                                                                
  Overall                                                                    1.34 (1.16--1.53)   **0.000**     1.22 (0.78--1.92)   0.38               1.45 (1.23--1.70)   **0.000**   1.12 (0.72--1.76)   0.61        1.43 (1.22--1.67)   **0.000**
  Chinese                                                                    1.41 (1.21--1.63)   **0.000**     1.59 (0.95--2.67)   0.08               1.47 (1.24--1.75)   **0.000**   1.45 (0.86--2.43)   0.16        1.48 (1.25--1.75)   **0.000**
  PB                                                                         1.30 (1.11--1.52)   **0.001**     1.19 (0.73--1.94)   0.48               1.40 (1.17--1.68)   **0.000**   1.11 (0.68--1.80)   0.68        1.38 (1.16--1.64)   **0.000**
  HWE                                                                        1.41 (1.21--1.63)   **0.000**     1.59 (0.95--2.67)   0.08               1.47 (1.24--1.75)   **0.000**   1.45 (0.86--2.43)   0.16        1.48 (1.25--1.75)   **0.000**

**Notes.**

Athe major alleleBthe minor alleleCIconfidence intervalORodds ratioPBpopulation basedHBhospital basedSNPsingle-nucleotide polymorphismHWEsubgroup excluding the study departing from HWE

![Forest plots of *CTLA-4* polymorphisms and breast cancer risk.\
(A) [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) under G *vs.* A; (B) [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243)) under AA *vs.* GG; (C) [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) under AG + GG *vs.* AA. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](peerj-05-2815-g002){#fig-2}

There were four studies all of which were from China with 1,402 cases and 1,407 controls investigating the relationship between and breast cancer susceptibility and *CTLA-4* [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) polymorphism. The results presented a significantly lower breast cancer risk in homozygous and recessive genetic models in Chinese women (AA *vs.* GG: *OR* = 0.68, 95% CI \[0.49--0.95\], *P* = 0.02, [Fig. 2B](#fig-2){ref-type="fig"}; AA *vs.* GG + GA: *OR* = 0.77, 95% CI \[0.61--0.97\], *P* = 0.02).

For *CTLA-4* [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) polymorphism, we aseessed 4 studies containing 1,560 cases and 1,489 controls. Overall, our analysis did not suggest any association between [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) and breast cancer susceptibility. However, when stratifying by source of control, [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) was observed to increase breast cancer risk based on population in three genetic models (C *vs.* T: *OR* = 1.19, 95% CI \[1.05--1.34\], *P* = 0.007; CC *vs.* TT: *OR* = 1.37, 95% CI \[1.05--1.78\], *P* = 0.02; CT *vs.* TT: *OR* = 1.22, 95% CI \[1.02--1.47\], *P* = 0.03).

Five studies involving 1,656 cases and 1,625 controls investigated the breast cancer risk with*CTLA-4* [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) polymorphism. We observed a higher risk in overall analysis under three models (G *vs.* A: *OR* = 1.34, 95% CI \[1.16--1.53\], *P* = 0.000; AG *vs.* AA: *OR* = 1.45, 95% CI \[1.23--1.70\], *P* = 0.000; AG + GG *vs.* AA: *OR* = 1.43, 95% CI \[1.22--1.67\], *P* = 0.000, [Fig. 2C](#fig-2){ref-type="fig"}). The results were similar in Chinese subgroup. When stratifying by source of control, [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) was also noted to increase breast cancer risk in allelic and heterozygous models based on population.

Heterogeneity analysis and sensitivity analysis
-----------------------------------------------

As presented in [Table 4](#table-4){ref-type="table"}, no obvious heterogeneity was detected for the four *CTLA-4* polymorphisms in most of the genetic models. For the few in which existed significant heterogeneity (*I*^2^ \> 50%), random-effects model was applied.
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###### Heterogeneity-analysis results of *CTLA-4* polymorphisms and BC risk.

![](peerj-05-2815-g008)

  SNP                                                                        B *vs.* A   BB *vs.* AA   AB *vs.* AA   BB *vs.* AA + AB   AB + BB *vs.* AA                                                      
  -------------------------------------------------------------------------- ----------- ------------- ------------- ------------------ ------------------ --- ----- ------ --- ----- ------ --- ----- ------ ---
  +49A\>G ([rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775))                                                                                                                                        
  Overall                                                                    0%          0.46          F             45%                0.09               F   29%   0.21   F   27%   0.22   F   41%   0.12   F
  Chinese                                                                    12%         0.34          F             40%                0.15               F   51%   0.09   R   0%    0.59   F   60%   0.04   R
  PB                                                                         6%          0.38          F             39%                0.14               F   39%   0.15   F   0%    0.56   F   51%   0.07   R
  +6230G\>A ([rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243))                                                                                                                                    
  Chinese                                                                    58%         0.07          R             8%                 0.36               F   0%    0.38   F   0%    0.78   F   53%   0.09   R
  PB                                                                         60%         0.08          R             24%                0.27               F   16%   0.31   F   0%    0.58   F   46%   0.16   F
  −1722T\>C ([rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618))                                                                                                                                      
  Overall                                                                    52%         0.10          R             51%                0.10               R   7%    0.36   F   35%   0.22   F   39%   0.18   F
  Chinese                                                                    64%         0.06          R             59%                0.09               R   37%   0.21   F   31%   0.23   F   57%   0.10   R
  PB                                                                         0%          0.74          F             0%                 0.45               F   0%    0.99   F   0%    0.37   F   0%    0.98   F
  −1661A\>G ([rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808))                                                                                                                                    
  Overall                                                                    27%         0.24          F             9%                 0.35               F   14%   0.32   F   6%    0.37   F   24%   0.26   F
  Chinese                                                                    0%          0.48          F             0%                 0.99               F   32%   0.22   F   0%    0.98   F   24%   0.27   F
  PB                                                                         39%         0.18          F             31%                0.23               F   27%   0.25   F   30%   0.24   F   34%   0.21   F
  HWE                                                                        0%          0.48          F             0%                 0.99               F   32%   0.22   F   0%    0.98   F   24%   0.27   F

**Notes.**

EMEffects modelFfixed effects modelRrandom effects modelPBpopulation basedHBhospital basedSNPsingle-nucleotide polymorphismHWEsubgroup excluding the study departing from HWE

Each study was sequentially removed to assess the impact of single study on the combined ORs. The result showed that the omission of any study didn't alter the overall estimations substantially, indicating that our meta-analysis results were robust ([Fig. 3](#fig-3){ref-type="fig"}).

![Sensitivity analysis of *CTLA-4* polymorphisms and breast cancer risk.\
(A) [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) under G *vs.* A; (B) [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) under AA *vs.* GG + GA; (C) [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) under TC *vs.* TT; (D) [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) under G *vs.* A. Each point represents the pooled OR after omitting single study in left column. The two ends of the dotted lines represent the 95% CI.](peerj-05-2815-g003){#fig-3}

Publication bias
----------------

We implemened Begg's funnel plot and Egger's test to asesess the publication bias. As shown in [Fig. 4](#fig-4){ref-type="fig"}, funnel plot failed to display obvious asymmetry. The Egger's test result didn't reveal any publication bias for the four SNPs in *CTLA-4* gene and breast cancer risk either ([Table 5](#table-5){ref-type="table"}, *P* \> 0.05).

![Begg's funnel plots of publication bias for the association of *CTLA-4* polymorphisms and breast cancer risk.\
(A) [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775), (B) [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243), (C) [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618), (D) [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) under the allelic model. Each point represents a single study for the indicated association.](peerj-05-2815-g004){#fig-4}

Discussion
==========

It was reported that mutation in human *CTLA-4* gene resulted in quantitative reduction of CTLA-4 expression and led to a severe immunoregulatory disorder ([@ref-14]). Several investigations have suggested that particular *CTLA-4* gene polymorphisms are linked to cancer development or progression ([@ref-6]; [@ref-23]; [@ref-28]). However, the results from those studies remained conflicting. In one previous study, the author found that [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) and [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) polymorphisms in *CTLA-4* increased the breast cancer risk whereas [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) and [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) polymorphisms did not have significant associations with breast cancer risk ([@ref-16]). However, in other studies, [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) and [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) polymorphisms were found to reduce the risk of breast cancer while [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) did not associated with breast cancer risk ([@ref-22]; [@ref-28]). Since CTLA-4 is important in carcinogenesis and a single study does not have enough statistical power to detect the effects, we carried out this meta-analysis which synthesized the results of the included studies with a statistical analysis of the data from these studies to draw a more reliable conclusion about the association between *CTLA-4* SNPs and breast cancer susceptibility.

In the present meta-analysis, we identified that *CTLA-4* [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) had an association with breast cancer susceptibility. We observed a significantly decreased risk in both overall and subgroup analysis in different genetic models. Some previous meta-analyses have also involved the relationship between [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) polymorphism and several tumor sites including breast cancer ([@ref-7]; [@ref-8]; [@ref-27]; [@ref-32]). The results suggested the A allele of [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) may contribute to breast cancer susceptibility. Our result confirmed that the A allele of *CTLA-4* [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775) polymorphism has more possibility to increase breast cancer risk than G allele. Nevertheless, our study differs from theirs because we specifically focused on breast cancer and our meta-analysis included more studies than theirs. Therefore, our results are more reliable.
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###### Egger's test result of *CTLA-4* polymorphisms and BC risk based on allele frequency.
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  SNP                                                            Coefficient   SE     *t*     *P*     95% CI
  -------------------------------------------------------------- ------------- ------ ------- ------- ---------------
  [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775)     0.71          1.13   0.63    0.557   −2.19--3.61
  [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243)   −5.19         3.20   −1.62   0.246   −18.94--0.56
  [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618)     −0.03         3.17   −0.01   0.993   −13.67--13.61
  [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808)   1.26          2.82   0.45    0.686   −7.70--10.21

**Notes.**

SNPsingle-nucleotide polymorphism95% CI95% confidence intervalSEstandard error

*CTLA-4* [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) polymorphism was found to decrease breast cancer risk under homozygous and recessive genetic models in Chinese. Our results implied that individuals carry AA genotype are less susceptible to breast cancer than those carry GG or (GG + GA) genotypes. Previous studies also found that [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) was associated with breast cancer susceptibility as a subgroup of several cancer sites ([@ref-31]; [@ref-33]). The results were similar with our research, but our our meta-analysis included one more study and have more statistical power.

We didn't find any relationship between *CTLA-4* [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) and breast cancer risk in the overall analysis under any genetic model. However, there was a higher risk in the population-based group under all the genetic models except recessive model. Considering that we selected only four eligible studies and most of them were small-size sample (\<500), these results need to be taken with caution. One previous study found a positive signal of [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) polymorphism with breast cancer ([@ref-16]) while other two studies showed negative signal ([@ref-6]; [@ref-23]). So further researches with larger sample size should be designed and implemented to validate or refute these conclusions.

In contrast, *CTLA-4* [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) polymorphism was realated to an increased breast cancer risk in both overall and Chinese population in allelic, heterozygous and dominant models. This suggested that *CTLA-4* −1661G allele is more likely to be a risk factor of breast cancer than A allele. Previous meta-analysis also found [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) may increase cancer risk especially for breast cancer ([@ref-8]; [@ref-31]; [@ref-33]). But these studies investigated the association of this single SNP with various types of cancer while our study specifically focused on breast cancer and investigated several SNPs. Notably, for this SNP, the *P*-value of HWE in control of one study was less than 0.05 ([@ref-6]), suggesting that the study population was not representative of a broad population. Nevertheless, we decided to keep this study because deleting it did not affect the pooled ORs significantly.

Several limitations of our research should be noticed. Firstly, the sample size in this meta-analysis was relatively small, especially for [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243), [rs733618](http://www.ncbi.nlm.nih.gov/snp/?term=rs733618) and [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) polymorphisms. Secondly, our results need to be interpreted with caution since we did not find any studies from Europe, Africa or America and most of the included studies were from China. Therefore, more studies with large population and more ethnic groups are needed to provide sufficient statistical power. Thirdly, other factors such as environmental variants, age, and living habit are generally considered to contribute to cancer susceptibility. Lacking data of these factors for adjustment may impact the estimation of breast cancer risk. Lastly, bias may still exist because we failed to find any studies of other races and we did not have access to gray literature.

Conclusion
==========

In summary, our meta-analysis suggests that [rs231775](http://www.ncbi.nlm.nih.gov/snp/?term=rs231775), [rs3087243](http://www.ncbi.nlm.nih.gov/snp/?term=rs3087243) and [rs4553808](http://www.ncbi.nlm.nih.gov/snp/?term=rs4553808) polymorphisms in human *CTLA-4* gene significantly associated with breast cancer susceptibility in Asians, particularly in the Chinese population. In consideration of the limitations of our work, further large-scale studies including multi-racial populations are required to confirm our findings.

Supplemental Information
========================

10.7717/peerj.2815/supp-1

###### PRISMA checklist

###### 

Click here for additional data file.

10.7717/peerj.2815/supp-2

###### Excluded articles and the reasons for exclusion of each article

###### 

Click here for additional data file.

Additional Information and Declarations
=======================================

The authors declare there are no competing interests.

[Zhiming Dai](#author-1){ref-type="contrib"} and [Tian Tian](#author-2){ref-type="contrib"} performed the experiments, analyzed the data, wrote the paper.

[Meng Wang](#author-3){ref-type="contrib"} performed the experiments, analyzed the data, reviewed drafts of the paper.

[Xinghan Liu](#author-4){ref-type="contrib"}, [Kang Liu](#author-7){ref-type="contrib"} and [Peng Xu](#author-9){ref-type="contrib"} contributed reagents/materials/analysis tools.

[Shuai Lin](#author-5){ref-type="contrib"} reviewed drafts of the paper.

[Pengtao Yang](#author-6){ref-type="contrib"}, [Yi Zheng](#author-8){ref-type="contrib"}, [Meng Liu](#author-10){ref-type="contrib"} and [Xuewen Yang](#author-11){ref-type="contrib"} prepared figures and/or tables.

[Zhijun Dai](#author-12){ref-type="contrib"} conceived and designed the experiments, reviewed drafts of the paper.

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The study was approved by the Institutional Review Board of the Second Affiliated Hospital, Xi'an Jiaotong University (Xi'an, China). No. 2016108.

The following information was supplied regarding data availability:

The raw data is included in [Tables 1](#table-1){ref-type="table"} and [2](#table-2){ref-type="table"}.
